These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8168099)

  • 1. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
    Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
    Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
    Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
    Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
    Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
    Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
    Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
    Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
    Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
    Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
    Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
    Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IPdR: a novel oral radiosensitizer.
    Saif MW; Berk G; Cheng YC; Kinsella TJ
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1415-24. PubMed ID: 17714027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
    Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
    Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
    Chang CN; Doong SL; Cheng YC
    Biochem Pharmacol; 1992 May; 43(10):2269-73. PubMed ID: 1599512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
    Kinsella TJ; Kinsella MT; Hong S; Johnson JP; Burback B; Tosca PJ
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):323-34. PubMed ID: 17562042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
    Kinsella TJ; Kinsella MT; Seo Y; Berk G
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts.
    Kinsella TJ; Glennon MC; Kunugi KA; Lindstrom MJ
    Clin Cancer Res; 1996 Jun; 2(6):981-9. PubMed ID: 9816259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.
    Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM
    J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.
    Harrington KJ; Syrigos KN; Uster PS; Zetter A; Lewanski CR; Gullick WJ; Vile RG; Stewart JS
    Br J Cancer; 2004 Jul; 91(2):366-73. PubMed ID: 15199395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
    Yuan X; Dillehay LE; Williams JR; Williams JA
    Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
    Kassis AI; Adelstein SJ; Mariani G
    Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
    Philip PA; Kaklamanis L; Carmichael J; Tonkin K; Morrison H; Gatter K; Harris AL
    Br J Cancer; 1993 Apr; 67(4):644-9. PubMed ID: 8471420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
    Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
    J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
    Mariani G; Di Sacco S; Bonini R; Di Luca L; Buralli S; Bonora D; Ricci S; Baranowska-Kortylewicz J; Adelstein SJ; Falcone A; Kassis AI
    Acta Oncol; 1996; 35(7):941-5. PubMed ID: 9004775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
    Kummar S; Anderson L; Hill K; Majerova E; Allen D; Horneffer Y; Ivy SP; Rubinstein L; Harris P; Doroshow JH; Collins JM
    Clin Cancer Res; 2013 Apr; 19(7):1852-7. PubMed ID: 23403637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.